21 results on '"Abella, Steve"'
Search Results
2. Abstract PR09: Gene expression profiling in wild-type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab
3. A Survey of Clinical Productivity and Current Procedural Terminology (CPT) Coding Patterns of Pediatric Hematologist/Oncologist
4. Chromosome analyses of 16 cases of Wilms tumor: different pattern in unfavorable histology
5. PD47-08 FIERCE-21: PHASE 2 STUDY OF VOFATMAB (B-701), A SELECTIVE INHIBITOR OF FGFR3, AS SALVAGE THERAPY IN METASTATIC UROTHELIAL CARCINOMA (MUCC)
6. FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).
7. Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy
8. A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
9. Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)
10. Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling
11. Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
12. Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
13. Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL)
14. Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL)
15. AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo
16. Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).
17. Evaluation of Relative Dose Intensity (RDI) by Age in Patients (pts) with Non-Hodgkin Lymphoma (NHL) Receiving Pegfilgrastim and CHOP Based Chemotherapy
18. Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies
19. Underreporting of Myelotoxicity with Emerging Regimens for Selected Hematologic Malignancies
20. Epidermal Abnormalities May Distinguish Type 2 from Type 1 and Type 3 of Gaucher Disease
21. AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitroand In Vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.